For all press and media enquiries please contact mediarelations@chiesi.com
Cary, N.C., June 12, 2018 – Chiesi USA (key-A-zee), a specialty pharmaceutical company based in Cary, N.C., and the Italian biotech Holostem Terapie Avanzate S.r.l., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an investigational product,…
Lamzede ® (velmanase alfa) is the first enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis (AM) AM is an ultra-rare disorder presenting a broad range of symptoms and its long-term prognosis is generally poor, with…
The pharmaceutical Group’s new head office, which will guide its growth and internationalisation strategies, will be located in Parma and will house around 540 people. People, innovation, sustainability: three words which sum up the philosophy behind this new project, developed on the basis of a new…
The Chiesi Group, represented by the CEO Ugo Di Francesco, took part at the French International Summit. Event wanted by the President of the French Republic Emmanuel Macron, who saw protagonists CEOs and Presidents of the world's largest multinational companies, members of the French Parliament,…
The 2017 edition of the EU Industrial R & D Investment Scoreboard of the European Commission places Chiesi Group at the top of the Italian pharmaceutical companies in terms of investments in Research and Development. Compared to the previous year, the growth of Chiesi Group's investments (12.6%) is…
The award is assigned to 10 affiliates of Chiesi Group. In 2018, the Group celebrates Top Employers for the 10th year running in Italy and for the 6th year running in Europe. The independent research by Top Employers Institute rewards the Company excellence in HR practices, thanks to the employee…
Lamzede ® (velmanase alfa) is the first pharmacological therapy for the treatment of Alpha- Mannosidosis (AM), an ultra-rare, disabling, genetic disorder 1 AM is a lysosomal storage disorder caused by the deficiency in the activity of the enzyme alpha-mannosidase, involved in the cellular breakdown…
The TRIBUTE study showed superiority of Chiesi’s extrafine formulation triple combination, Trimbow ® (beclometasone/formoterol/glycopyrronium) over Ultibro ® Breezhaler ® (indacaterol/glycopyrronium) in terms of rate of moderate-to-severe exacerbations in patients affected by Chronic Obstructive…
Chiesi completed a long-term clinical study with its extrafine fixed-dose triple combination inhaler (Trimbow ® ) in a single pressurised metered dose inhaler (pMDI) for COPD patients. Trimbow met the primary endpoint showing superiority vs Ultibro ® in reducing COPD exacerbations. Full study…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
